- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05919693
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)
A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Caba, Argentinië, 1023
- Caba, Argentina
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentinië, C1121ABB
- Ciudad Autonoma Buenos Aires
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
London, Verenigd Koninkrijk, W1G7LB
- London, UK
-
-
England
-
London, England, Verenigd Koninkrijk, NW10 7NS
- London, England
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85032
- Phoenix, AZ
-
-
California
-
Bakersfield, California, Verenigde Staten, 93309
- Bakersfield, CA
-
Modesto, California, Verenigde Staten, 95356
- Modesto, CA
-
Mountain View, California, Verenigde Staten, 94040
- Mountain View, CA
-
Sacramento, California, Verenigde Staten, 95825
- Sacramento, CA
-
Sacramento, California, Verenigde Staten, 95841
- Sacramento, CA
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- Colorado Springs, Colorado
-
Lakewood, Colorado, Verenigde Staten, 80288
- Lakewood, CO
-
-
Florida
-
Pompano Beach, Florida, Verenigde Staten, 33064
- Pompano Beach
-
-
Illinois
-
Lemont, Illinois, Verenigde Staten, 60439
- Lemont, NV
-
-
Maryland
-
Hagerstown, Maryland, Verenigde Staten, 21740
- Hagerstown, MD
-
-
Nevada
-
Reno, Nevada, Verenigde Staten, 89502
- Reno, NV
-
-
South Carolina
-
West Columbia, South Carolina, Verenigde Staten, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Verenigde Staten, 38138
- Germantown, TN
-
Knoxville, Tennessee, Verenigde Staten, 37922
- Knoxville, TN
-
Nashville, Tennessee, Verenigde Staten, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Verenigde Staten, 79606
- Abilene, TX
-
Amarillo, Texas, Verenigde Staten, 79109
- Amarillo, TX
-
Austin, Texas, Verenigde Staten, 78705
- Austin, TX
-
Bellaire, Texas, Verenigde Staten, 77401
- Bellaire, TX
-
Dallas, Texas, Verenigde Staten, 75231
- Dallas, TX
-
Katy, Texas, Verenigde Staten, 77494
- Katy, TX
-
McAllen, Texas, Verenigde Staten, 78503
- McAllen, TX
-
Plano, Texas, Verenigde Staten, 75075
- Plano, TX
-
Round Rock, Texas, Verenigde Staten, 78681
- Round Rock, TX
-
San Antonio, Texas, Verenigde Staten, 78240
- San Antonio, TX
-
The Woodlands, Texas, Verenigde Staten, 77384
- The Woodlands, TX
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
- Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
- DME patients must have vision loss in the study eye
- NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye
Exclusion Criteria:
- Be pregnant or breastfeeding
- History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
- Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
- Any other condition except for DME or NVAMD or that could affect interpretation of study assessments
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dose 1
Part 1 MAD Portion Dose 1 - Low Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Dose 2
Part 1 MAD Portion Dose 2 - Low-Mid Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Dose 3
Part 1 MAD Portion Dose 3 - Mid-High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Dose 4
Part 1 MAD Portion Dose 4 - High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: DME Medium Dose
Part 2 Naïve DME monotherapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: DME High Dose
Part 2 Naïve DME monotherapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Naïve NVAMD Medium Dose
Part 2 Naïve NVAMD combination therapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Naïve NVAMD High Dose
Part 2 Naïve NVAMD combination therapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Experienced NVAMD Medium Dose
Part 2 Experienced NVAMD combination therapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
|
Experimenteel: Experienced NVAMD High Dose
Part 2 Experienced NVAMD combination therapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Tijdsspanne: Up to approximately 12 weeks
|
Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator. |
Up to approximately 12 weeks
|
|
Number of Participants Who Experienced an Adverse Event (AE)
Tijdsspanne: Up to approximately 12 weeks
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to approximately 12 weeks
|
|
Number of Participants Who Experienced a Serious Adverse Event (SAE)
Tijdsspanne: Up to approximately 24 weeks
|
An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant |
Up to approximately 24 weeks
|
|
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Tijdsspanne: Baseline and Week 12
|
Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant. |
Baseline and Week 12
|
|
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented. |
Baseline and Week 12
|
|
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented. |
Baseline and Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
Tijdsspanne: Baseline and 12 weeks
|
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented. |
Baseline and 12 weeks
|
|
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
Tijdsspanne: Baseline and 12 weeks
|
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented. |
Baseline and 12 weeks
|
|
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Tijdsspanne: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Tijdsspanne: Baseline and Week 12
|
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening). |
Baseline and Week 12
|
|
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Tijdsspanne: Baseline and Week 12
|
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening). |
Baseline and Week 12
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EYE103-101
- MK-3000-003 (Andere identificatie: Merck)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .